ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-TF/TOP1i Antibody-drug Conjugate XB371

Its studies are led by Exelixis.

Furthest: phase 1, since Aug 8, 20251 company-led study, 1 open or runningNext primary completion: Nov 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Exelixis11 open or runningphase 1since Aug 8, 2025Aug 8, 2025Nov 30, 2027phase 1 · NCT07123103

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 8, 2025First study: phase 1 study in Solid TumorsFirst studyNCT07123103 · 150 planned · United States

Ahead

  1. Nov 30, 2027Primary completion: phase 1 study in Solid TumorsNCT07123103

TargetBeta

F3 →read by rule
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody against human tissue factor (TF; F3; coagulation factor III; thromboplastin; CD142) ”NCIt, by rule

Other programs on F3

ProgramCompanyFurthest phaseStudies
tisotumab vedotinrulePfizerphase 411
Anti-TF/TOP1i Antibody-drug Conjugate XNW28012ruleEvopoint Biosciencesphase 33
Anti-TF Antibody-drug Conjugate MRG004Arulelepu-biopharma-co-ltdphase 32
SHR-4375Jiangsu HengRui Medicinephase 22
Anti-TF/Exatecan Antibody-drug Conjugate STRO-004rulesutro-biopharma-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07123103Solid Tumors · United States1RecruitingNov 30, 2027150

How it is read

Names in the registry

  • “XB371”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.